Counter-offer For Insurance Company Settlement

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Condition: Psoriasis

Intervention: Biological: teplizumab

Sponsors: MacroGenics; Eli Lilly and Company

Not yet recruiting - verified August 2009

http://clinicaltrials.gov/ct2/show/NCT00954915?term=psoriasis&rcv_d=14